Screening for Research Participants
Recruiting
This study will allow National Eye Institute (NEI) doctors the opportunity to examine people with eye disease, whether the diagnosis is known or not, to determine if they are eligible for other NEI research studies. No treatment is offered in this study. People of all ages with various eye conditions, including genetic conditions, eye movement disorders, inflammatory eye diseases, retinal diseases and external eye diseases, may be eligible for this study. Participants undergo various tests and... Read More
Gender:
ALL
Ages:
Between 2 years and 100 years
Trial Updated:
05/16/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Eye Diseases
A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer
Recruiting
This trial will evaluate the efficacy and safety of various therapies in patients with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated non-small cell lung cancer (NSCLC) tumors that meet protocol-specified biomarker criteria
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: City of Hope Comprehensive Cancer Center, Duarte, California +38 locations
Conditions: Non-small Cell Lung Cancer
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
Recruiting
The primary objective of the Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC) (INSIGHT 012) trial is to compare the safety and efficacy of a single infusion of anti-COVID-19 hyperimmune intravenous immunoglobulin (hIVIG) versus placebo among adults with recently diagnosed severe acute respiratory syndrome - coronavirus 2 (SARS-CoV2) infection who do not require hospitalization. The primary endpoint of this double-blind randomized trial is a five-category ordinal outcome that asse... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Southern Arizona VA Healthcare System (074-009), Tucson, Arizona +61 locations
Conditions: COVID, SARS-CoV2 Infection, Covid19
Combining Aerobic Exercise and Virtual Reality for Cognitive-motor Rehabilitation in PD
Recruiting
This project will provide preliminary data on the feasibility and effects of exercise and VR on motor behavior and neuroplasticity in PD. Results from this work will provide insight into whether combination interventions utilizing AE and VR have parallel effects on cognition, gait, and neuroplasticity in PD.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
05/16/2025
Locations: UT Health San Antonio- Dept. of Physical Therapy, San Antonio, Texas
Conditions: Parkinson's Disease
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Recruiting
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II classical Hodgkin lymphoma. Brentuximab vedotin is in a class of medications called antibody-drug conjugates. It is made of a monoclonal antibody called brentuximab that is linked to a cytotoxic agent called vedotin. Brentuximab attaches to CD30 posi... Read More
Gender:
ALL
Ages:
Between 5 years and 60 years
Trial Updated:
05/16/2025
Locations: USA Health Strada Patient Care Center, Mobile, Alabama +346 locations
Conditions: Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B
Recruiting
Background: Chronic hepatitis B virus (HBV) infection affects 292 million people worldwide; 887,000 die each year from cirrhosis, liver cancer, and related issues. Treatment options are limited. Objective: To test 2 drugs (VIR-2218 and peginterferon) in people with mild or inactive HBV infection. Eligibility: People aged 18 to 65 years with mild or inactive HBV infection. Design: Participants will be screened. They will have blood tests and an eye exam. They will have imaging scans of the... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/16/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Chronic Hepatitis B
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Recruiting
This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. It is not yet known if giving r... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +186 locations
Conditions: Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features
Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer
Recruiting
This phase I trial tests the safety, side effects, and best dose of abemaciclib in combination with 5-fluorouracil and how well it works in treating patients with colorectal cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and that has not responded to treatment (refractory). Abemaciclib, a type of cyclin-dependent kinase inhibitor, blocks certain proteins, which may help keep tumor cells from growing. 5-fluorouracil, a type of antimetabo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California +4 locations
Conditions: Metastatic Microsatellite Stable Colorectal Carcinoma, Refractory Microsatellite Stable Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8
Study to Assess Clinical Activity of Zelenectide Pevedotin in Participants With Advanced Breast Cancer
Recruiting
This is a global, multicenter, open-label study that aims to assess the efficacy and safety of zelenectide pevedotin in participants with NECTIN4-amplified recurrent, unresectable, or metastatic breast cancer who have received prior therapy (see inclusion criteria below). The study will comprise of 2 cohorts. Cohort A will include participants with hormone receptor positive/ human epidermal growth factor receptor 2 negative \[HR+/HER2-\] breast cancer, whereas Cohort B will include participants... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Siteman Cancer Center, Saint Louis, Missouri +4 locations
Conditions: Breast Cancer
Natural History of Individuals With Immune System Problems That Lead to Fungal Infections
Recruiting
Background: - The immune system is made up of special cells, tissues, and organs that fight infections. Problems with this system may lead to frequent, severe, or unusual fungal infections. These infections are often difficult to treat. Researchers want to collect blood and tissue samples from people who have unusual, persistent or severe fungal infections or immune problems that increase the risk of these infections. Objectives: - To collect medical information and samples for a long-term st... Read More
Gender:
ALL
Ages:
Between 1 day and 99 years
Trial Updated:
05/16/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Chronic Mucocutaneous Candidiasis, Invasive Aspergillosis, CARD9, APECED
Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer
Recruiting
This phase II trial studies how well the addition of olaparib to the usual treatment, temozolomide, works in treating patients with neuroendocrine cancer (pheochromocytoma or paraganglioma) that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Poly (adenosine diphosphate \[ADP\]-ribose) polymerases (PARPs) are proteins that help repair deoxyribonucleic acid (DNA) mutations. PARP inhibitors, such as olap... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
05/16/2025
Locations: Anchorage Associates in Radiation Medicine, Anchorage, Alaska +162 locations
Conditions: Advanced Adrenal Gland Pheochromocytoma, Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Paraganglioma, Unresectable Adrenal Gland Pheochromocytoma, Unresectable Paraganglioma, Stage III Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8, Stage IV Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8
The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
Recruiting
Background: About 5% to 10% of differentiated thyroid cancers become resistant to standard treatment with radioactive iodine. In these cases, treatment options are limited and generally not effective. Researchers want to see if they can better detect thyroid tumors by using a compound called 68Gallium-DOTATATE. This compound may bind to a tumor and make it visible during a positron emission tomography/computed tomography (PET/CT) scan. This information might help guide future research and treat... Read More
Gender:
ALL
Ages:
Between 18 years and 98 years
Trial Updated:
05/16/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Metastic Thyroid Cancer